SAN DIEGO: PhenoVista Biosciences introduced a strategic funding by Fujifilm Corporation, Tokyo.
Fujifilm Corporation’s Life Sciences Corporate Venture Capital (LS-CVC) strategic funding fund is investing in PhenoVista to speed up the event of new high-content screening (HCS) assay services utilizing FUJIFILM iCell® differentiated induced pluripotent stem cells (iPSCs) and PhenoVista’s cutting-edge imaging technologies.
This funding builds upon the existing strategic alliance between FUJIFILM Corporation subsidiary, FUJIFILM Cellular Dynamics, Inc., a number one global developer and producer of human iPSCs, and PhenoVista.
FUJIFILM Cellular Dynamics goals to additional expand its drug-discovery enterprise through this alliance initiated in November 2021 by collaboratively developing high-content, imaging-based assays utilizing human iPSC-derived differentiated cells, that are extremely related organic systems.
These HCS assay services utilizing iPSCs are able to monitoring complex intracellular functions, such as cell health, mitochondrial health, and synapse formation, in particular person human cells that are concerned in illness progression, supporting pharmaceutical companies of their drug-discovery processes.
“Fujifilm’s funding will speed up an thrilling phase of growth for PhenoVista, additional solidifying our place because the chief in imaging-based evaluation of complex cell models,” said James G. Evans, CEO and co-founder of PhenoVista Biosciences.
“Through this deepening relationship, PhenoVista’s present and future companions and collaborators will have early entry to new cell fashions from Fujifilm, our long-trusted supply of validated iPS cell fashions inside the most related therapeutic areas, and we will proceed to develop new fashions in each our bespoke and Ready-2-Go service platforms.”
“Fujifilm is dedicated to fixing societal points through the creation of new values from the alignment with companions that offer technological capabilities for a strategic match with our life sciences portfolio,” said Takatoshi Ishikawa, general supervisor of Life Sciences Strategy Headquarters, FUJIFILM Corporation.
“The funding through the LS-CVC fund consolidates the partnership with PhenoVista to speed up pioneering the field of iPSC-derived services, which helps guarantee that extra sufferers get new treatments they want faster.”
“Fujifilm brings a wealth of experience in imaging to the life sciences arena, and in collaboration with PhenoVista, will proceed to assist our shared customers with their environment friendly drug-discovery processes through the mixture of extremely relevant, human cell types and extremely effective HCS capabilities and experience,” said Tomoyuki Hasegawa, president and CEO, FUJIFILM Cellular Dynamics, Inc.
“This funding will proceed to support the expansion and expansion of our iCell enterprise along with our superior providing of cell applications by rising buyer entry to HCS assays utilizing our iPSCs.”
Launched in February 2022, LS-CVC is a newly established group inside Fujifilm’s Life Sciences Strategy Headquarters in Tokyo. Fujifilm is initially investing 7B¥ (about 50 million USD) to begin the fund, targeting cutting-edge biotechnology primarily through partnerships with early-stage companies across the world.
PhenoVista Biosciences is a number one supplier of disease-relevant cell-based assay services based in San Diego, California.